Skip to main content

CSL Research Acceleration Initiative

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life threatening medical conditions live full lives. 

Image

Background

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives. 

CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations. 

Successful applicants will receive funding of up to $400,000 USD over 2 years. 

Interested researchers are invited to:

  • Attend information webinars to learn more about the initiative: Thursday 23rd January 1pm ET / 12pm CT / 11am MT / 10am PT or Wednesday 05th February 11am ET / 10am CT / 9am MT / 8am PT
  • Contact Swapneeta Date at Swapneeta.Date@Vanderbilt.edu to express interest in applying and to obtain online application submission instructions.
  • Submit a non-confidential, 300 word abstract via the CSL online application portal by 20th February 2025.

The 2025 Research Acceleration Initiative will focus on research proposals that align with a CSL Therapeutic Area and are amenable to or include a Platform as illustrated below. Please see over page for specific Focus Areas

Email Swapneeta Date, CTTC Assistant Director of Life Sciences Collaborations, at Swapneeta.Date@Vanderbilt.edu to express interest in applying and to obtain online application submission instructions.